Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diana Bonderman

Showing results (51-60 of 127) with videos related to

Pageof 13
Sort By:
International Journal of Cardiology|January 8, 2017
Fluid status and outcome in patients with heart failure and preserved ejection fractionBenedikt Koell, Caroline Zotter-Tufaro, Franz Duca, et al.
Circulation. Heart Failure|March 11, 2025
Macitentan for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Pulmonary Vascular Disease: Results of the SERENADE Randomized Clinical Trial and Open-Label Extension StudySanjiv J Shah, Diana Bonderman, Barry A Borlaug, et al.
International Journal of Cardiology|May 8, 2020
Low serum potassium levels and diabetes - An unfavorable combination in patients with heart failure and preserved ejection fractionRoza Badr Eslam, Begüm Öztürk, Simon Panzer, et al.
Thrombosis and Haemostasis|March 1, 2005
Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertensionDiana Bonderman, Johannes Jakowitsch, Christopher Adlbrecht, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 2, 2008
Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertensionDiana Bonderman, Johannes Jakowitsch, Bassam Redwan, et al.
Plos One|July 31, 2015
Outcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular PerformanceGeorg Goliasch, Caroline Zotter-Tufaro, Stefan Aschauer, et al.
European Heart Journal. Cardiovascular Imaging|September 10, 2019
Native T1 time of right ventricular insertion points by cardiac magnetic resonance: relation with invasive haemodynamics and outcome in heart failure with preserved ejection fractionChristian Nitsche, Andreas A Kammerlander, Christina Binder, et al.
European Journal of Heart Failure|June 22, 2012
Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and designStefano Ghio, Diana Bonderman, Stephan B Felix, et al.
American Journal of Respiratory and Critical Care Medicine|September 18, 2007
Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertensionNika Skoro-Sajer, Friedrich Mittermayer, Adelheid Panzenboeck, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|July 11, 2022
Does [99mTc]-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) soft tissue uptake allow the identification of patients with the diagnosis of cardiac transthyretin-related (ATTR) amyloidosis with higher risk for polyneuropathy?Tim Wollenweber, Elisabeth Kretschmer-Chott, Raphael Wurm, et al.
Pageof 13

Showing results (51-60 of 127) with videos related to

Sort By:
Pageof 13
International Journal of Cardiology|January 8, 2017
Fluid status and outcome in patients with heart failure and preserved ejection fractionBenedikt Koell, Caroline Zotter-Tufaro, Franz Duca, et al.
Circulation. Heart Failure|March 11, 2025
Macitentan for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Pulmonary Vascular Disease: Results of the SERENADE Randomized Clinical Trial and Open-Label Extension StudySanjiv J Shah, Diana Bonderman, Barry A Borlaug, et al.
International Journal of Cardiology|May 8, 2020
Low serum potassium levels and diabetes - An unfavorable combination in patients with heart failure and preserved ejection fractionRoza Badr Eslam, Begüm Öztürk, Simon Panzer, et al.
Thrombosis and Haemostasis|March 1, 2005
Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertensionDiana Bonderman, Johannes Jakowitsch, Christopher Adlbrecht, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 2, 2008
Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertensionDiana Bonderman, Johannes Jakowitsch, Bassam Redwan, et al.
Plos One|July 31, 2015
Outcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular PerformanceGeorg Goliasch, Caroline Zotter-Tufaro, Stefan Aschauer, et al.
European Heart Journal. Cardiovascular Imaging|September 10, 2019
Native T1 time of right ventricular insertion points by cardiac magnetic resonance: relation with invasive haemodynamics and outcome in heart failure with preserved ejection fractionChristian Nitsche, Andreas A Kammerlander, Christina Binder, et al.
European Journal of Heart Failure|June 22, 2012
Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and designStefano Ghio, Diana Bonderman, Stephan B Felix, et al.
American Journal of Respiratory and Critical Care Medicine|September 18, 2007
Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertensionNika Skoro-Sajer, Friedrich Mittermayer, Adelheid Panzenboeck, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|July 11, 2022
Does [99mTc]-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) soft tissue uptake allow the identification of patients with the diagnosis of cardiac transthyretin-related (ATTR) amyloidosis with higher risk for polyneuropathy?Tim Wollenweber, Elisabeth Kretschmer-Chott, Raphael Wurm, et al.
Pageof 13